Position in BCAX
as of Mar 31, 2026
· filed May 5, 2026
Position Value
$11,315,798
+$1,740,892 QoQ
Shares Held
568,919
0.0% QoQ
Ownership
0.866%
of shares outstanding
% of Portfolio
2.38%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
7 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in BCAX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Aisling Capital Management LP holds $468,368,131 across 12 Biotechnology names. BCAX ranks #4 (2.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BBIO |
BridgeBio Pharma, Inc.
|
5,089,611 | $377,954,512 | |
| 2 | SNDX |
Syndax Pharmaceuticals Inc
|
1,316,806 | $30,760,588 | |
| 3 | GLUE |
Monte Rosa Therapeutics, Inc.
|
1,555,664 | $25,590,672 | |
| 4 | BCAX |
Bicara Therapeutics Inc.
This page
|
568,919 | $11,315,798 | |
| 5 | BBOT |
BridgeBio Oncology Therapeutics, Inc.
|
1,018,018 | $9,111,261 | |
| 6 | SRRK |
Scholar Rock Holding Corp
|
77,031 | $3,786,843 | |
| 7 | BMEA |
Biomea Fusion, Inc.
|
2,048,757 | $3,134,598 | |
| 8 | EPRX |
Eupraxia Pharmaceuticals Inc.
|
325,000 | $2,353,000 |
All Filings in BCAX
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $11,315,798 | 568,919 | Shares | Sole | 2026-05-05 | |
| 2025-12-31 | $9,574,906 | 568,919 | Shares | Sole | 2026-02-10 | |
| 2025-09-30 | $8,983,231 | 568,919 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $5,285,257 | 568,919 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $7,413,014 | 568,919 | Shares | Sole | 2025-05-13 | |
| 2024-12-31 | $9,910,568 | 568,919 | Shares | Sole | 2025-02-12 | |
| 2024-09-30 | $14,490,366 | 568,919 | Shares | Sole | 2024-11-13 | |
| No filing history on record for this holder in this stock. | ||||||